Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and DaVita (DVA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GoodRx Holdings (GDRX) and DaVita (DVA).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GoodRx Holdings (GDRX)
TD Cowen analyst Charles Rhyee maintained a Buy rating on GoodRx Holdings yesterday and set a price target of $4.00. The company’s shares closed last Friday at $2.92.
According to TipRanks.com, Rhyee is a 4-star analyst with an average return of
GoodRx Holdings has an analyst consensus of Hold, with a price target consensus of $3.04, an 8.6% upside from current levels. In a report issued on April 25, TipRanks – PerPlexity also upgraded the stock to Buy with a $2.50 price target.
See the top stocks recommended by analysts >>
DaVita (DVA)
TD Cowen analyst Ryan Langston maintained a Hold rating on DaVita yesterday and set a price target of $201.00. The company’s shares closed last Friday at $198.65.
According to TipRanks.com, Langston is a 1-star analyst with an average return of
DaVita has an analyst consensus of Moderate Buy, with a price target consensus of $213.50, which is an 8.6% upside from current levels. In a report issued on May 8, Truist Financial also maintained a Hold rating on the stock with a $205.00 price target.
Read More on GDRX:
Disclaimer & DisclosureReport an Issue
- Analyst Maintains Buy on GoodRx as High-Value Segments Gain Traction; Price Target Kept at $3.50
- GoodRx Earnings Call Highlights Pharma Direct Momentum
- GoodRx price target raised to $3.50 from $2.50 at Goldman Sachs
- Notable companies reporting after market close
- GoodRx reports Q1 adjusted EPS 7c, consensus 7c
